We would love to hear your thoughts about our site and services, please take our survey here.
Here is a puzzler. Orph Pharma IP Company Limited are owned by Open Orphan, and hold the immune modulator patent, they have also registered the trademark for Poolbeg Pharma, Poolbeg Pharma Limited is owned by Cathal, Ian O'Connell and 3 others, Cathal and Ian O'Connell also now own Orph Pharma Limited.
What does all this mean?
That would make a lot of sense, but if that is the case, the first spin-off is not the immune modulator HVO-001, as that was moved to Orph Pharma IP Company Limited.
So which spin out is Orph Pharma Limited for?
Some very strange events. Orph Pharma, set up and owned by Open Orphan, is now wholly owned by Cathal and Ian O'Connell.
It's not clear what Orph Pharma Limited is for or what assets it owns or intends to own, but it is now not for the benefit of Open Orphan shareholders.
This doesn't fill me with confidence...
This guy is in Poolbeg Pharma too
I think the antiviral taskforce will stump up a healthy grant to fund the last stages of the development of the immune modulator, no need to raise money from the market yet
Did everyone miss the big message in the original post?
We basically have a lot more competition in the covid-19 challenge study space, soon enough people can shop around.
At least we are further ahead of the competition for now.
Also a new LinkedIn company profile for each Twitter account
Ditto for the.org domains of each site, showing as recently registered on the holding site placemarker page
OrphBio.com OrphAntibodies.com and orphdata.com all registered domains but sat with holding company
6 new Orph Twitter accounts set up in March
@OrphPLC
@OrphDigital
@OrphAntibodies
@OrphPharmaPLC
@OrphBio
@DataOrph
Woodford was buying hVivo back when it was £1 plus. At merger Orph was 6p and hVivo valued at 14p , so at 50p per Orph share you'd break even with your £1 hVivo shares
Other drugs targeting this pathway have not worked, if Orph have cracked it it will be possibly ten's of billions on it's own https://www.google.com/url?sa=t&source=web&rct=j&url=http://onlinelibrary.wiley.com/doi/10.1002/art.24264/pdf&ved=2ahUKEwjVjMD4tPPvAhVioFwKHUf4DbY4ChAWMAZ6BAgIEAI&usg=AOvVaw2AdW4CgDF0_ZVp-D_rVi2W
Patent granted 30th December 2020
Target for covid-19 treatment
Target for Alzheimer's treatment
Target for cancer treatment
Patent https://patents.google.com/patent/WO2019122909A1/en
Search for uses of "p38 MAPK inhibitor"
Boom
Volume traded not a record but value traded is, previously high of 66m vol in a week was at about 12p, we did about 37m vol at about 40p
Doesn't he have to put serious offers to a shareholder vote?
Well there is the government grants that ConserV Biosciences have already started getting which could end up funding the trials and negate the need to fundraise
I think Apple, Google, or Samsung might just buy the whole company to get access to the data exclusively, and sell off the bits they don't need, if they came forward with a massive offer between £1-2 would Orph have to put the offer to us as shareholders to vote on?
Surely Orph will be providing ongoing data to DIM so there would still be a financial link between separate companies
I'd settle of a takeover offer of £2 per share, once I have all my spin-off shares